Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

This publication has 47 references indexed in Scilit:

• Emerging roles of E2Fs in cancer: an exit from cell cycle control
  Nature Reviews Cancer, 2009
• Hematopoietic Stem Cell Function and Survival Depend on c-Myc and N-Myc Activity
  Cell Stem Cell, 2008
• Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
  Blood, 2008
• Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells
  Cancer Research, 2006
• Anticancer activities of histone deacetylase inhibitors
  Nature Reviews Drug Discovery, 2006
• Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
  Blood, 2006
• Drosophila E2F1 Has Context-Specific Pro- and Antiapoptotic Properties during Development
  Developmental Cell, 2005
• Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
  Proceedings of the National Academy of Sciences, 2005
• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• Chronic Myeloid Leukemia
  New England Journal of Medicine, 1999